Alto Neuroscience, Inc. (NYSE:ANRO) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Alto Neuroscience, Inc. (NYSE:ANRO) have been given an average recommendation of “Moderate Buy” by the seven ratings firms that are currently covering the stock, Marketbeat reports. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $8.50.

A number of brokerages recently issued reports on ANRO. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Alto Neuroscience in a research report on Thursday, June 26th. Wedbush reaffirmed a “neutral” rating and set a $4.00 target price on shares of Alto Neuroscience in a research report on Thursday, May 15th.

Hedge Funds Weigh In On Alto Neuroscience

Hedge funds have recently made changes to their positions in the business. Point72 Asset Management L.P. grew its holdings in shares of Alto Neuroscience by 73.1% in the 4th quarter. Point72 Asset Management L.P. now owns 1,692,153 shares of the company’s stock worth $7,158,000 after purchasing an additional 714,461 shares during the last quarter. Armistice Capital LLC grew its holdings in shares of Alto Neuroscience by 1.5% in the 2nd quarter. Armistice Capital LLC now owns 1,624,000 shares of the company’s stock worth $3,573,000 after purchasing an additional 24,000 shares during the last quarter. Marshall Wace LLP grew its holdings in shares of Alto Neuroscience by 9.9% in the 2nd quarter. Marshall Wace LLP now owns 937,407 shares of the company’s stock worth $2,062,000 after purchasing an additional 84,417 shares during the last quarter. Vestal Point Capital LP grew its holdings in shares of Alto Neuroscience by 40.8% in the 4th quarter. Vestal Point Capital LP now owns 915,000 shares of the company’s stock worth $3,870,000 after purchasing an additional 265,000 shares during the last quarter. Finally, AWM Investment Company Inc. grew its holdings in shares of Alto Neuroscience by 31.1% in the 1st quarter. AWM Investment Company Inc. now owns 901,984 shares of the company’s stock worth $1,948,000 after purchasing an additional 214,153 shares during the last quarter.

Alto Neuroscience Trading Up 1.0%

Shares of ANRO stock opened at $3.15 on Monday. Alto Neuroscience has a 1 year low of $1.60 and a 1 year high of $15.04. The firm’s fifty day simple moving average is $2.70 and its 200 day simple moving average is $2.72. The firm has a market capitalization of $85.30 million, a P/E ratio of -1.32 and a beta of 1.84. The company has a current ratio of 18.43, a quick ratio of 18.43 and a debt-to-equity ratio of 0.18.

Alto Neuroscience (NYSE:ANRO) last announced its earnings results on Wednesday, August 13th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.08). As a group, sell-side analysts predict that Alto Neuroscience will post -2.54 EPS for the current year.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.